Processa Pharmaceuticals, Inc. has reported the presentation of two abstracts by David Young, President of R&D, at the AACR Annual Meeting 2024 held on April 11, 2024. The presentations included new data from the NGC Cap Phase 1b trial, focusing on the next generation capecitabine (NGC-Cap) which aims to increase 5-FU exposure while improving the safety profile compared to the standard capecitabine. Additional data was also presented in a full poster, which has been updated from its previous version and is now available on the company's website. Processa has stated that it has no obligation to update the information presented unless through standard public disclosure methods. The company uses its website for disclosing material non-public information in compliance with Regulation FD.

Processa Pharmaceuticals, Inc. has reported the presentation of two abstracts by David Young, President of R&D, at the AACR Annual Meeting 2024 held on April 11, 2024. The presentations included new data from the NGC Cap Phase 1b trial, focusing on the next generation capecitabine (NGC-Cap) which aims to increase 5-FU exposure while improving the safety profile compared to the standard capecitabine. Additional data was also presented in a full poster, which has been updated from its previous version and is now available on the company's website. Processa has stated that it has no obligation to update the information presented unless through standard public disclosure methods. The company uses its website for disclosing material non-public information in compliance with Regulation FD.